Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cadonilimab as Induction-adjuvant PD-1/CTLA-4 Bispecific Blockade Combined With Induction Chenotherapy and Concurrent Chemoradiotherapy in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma: a Multicenter, Randomized, Controlled, Multicenter, Phase 3 Clinical Trial

NCT05587374 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT05587374
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05587374 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cadonilimab as Induction-adjuvant PD-1/CTLA-4 Bispecific Blockade Combined With Induction Chenotherapy and Concurrent Chemoradiotherapy in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma: a Multicenter, Randomized, Controlled, Multicenter, Phase 3 Clinical Trial
Lead sponsor
Sun Yat-sen University
Phase
Phase 3
Overall status
Active, not recruiting
Start date
August 1, 2023
Completion date
August 1, 2029
Enrollment
490 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

nasopharyngeal cancer, nasopharyngeal carcinoma